Pfizer sees steady cash flows from a basket of diverse drugs, and the company's large size confers significant competitive advantages in developing new drugs. This heft, combined with a broad ...

When Pfizer (PFE) reports its third-quarter print on November 3rd, before market open, investors will be keenly watching for management’s updates to its cost-cutting program amid a widening gap ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Pfizer's post-COVID comeback is still only in the early stages.

Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.

Pfizer has been going through a period of transition.

Pfizer has delivered a solid 1 year return, yet the question many investors are circling is whether that share price now ...

A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...

Pfizer’s Jeff Legos discusses how science, AI and patient insights are shaping cancer research and the next generation of ...

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...